- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
May 13, 2024Robins Kaplan, Robert Bennett Recognized in Elite Trial Lawyers Awards
-
April 29, 2024Robins Kaplan Mourns Death of New York Associate Waleed Abbasi
-
April 29, 2024Robins Kaplan Secures $7.75 Million Verdict in Aerosol Dust Remover Abuse Case
-
May 20, 2024The Present and Future of DEI
-
May 23, 202414th Annual Disability Justice Seminar
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
May 2024Q&A with Anthony Froio
-
April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Invokana and Farxiga
Invokana, Farxiga, and other related type 2 diabetes drugs have been linked to a serious condition known as ketoacidosis.
Diabetes Drug Update – Invokana and Farxiga
In May 2015, the FDA issued a Safety Communication advising that certain Type 2 Diabetes drugs may result in a serious condition known as ketoacidosis.
Holly Dolejsi of Robins Kaplan LLP Appointed Co-Lead Counsel in Farxiga Multidistrict Litigation
Judge Lorna G. Schofield has appointed Robins Kaplan attorney Holly Dolejsi as co-lead counsel in multidistrict litigation (MDL) involving the diabetes drug Farxiga.
Robins Kaplan LLP Investigates Type 2 Diabetes Drugs and Severe Injuries, Including Ketoacidosis
Invokana and other related type 2 diabetes drugs have been linked to a serious condition known as ketoacidosis.
Robins Kaplan LLP Attorney Holly Dolejsi Appointed to Plaintiffs’ Steering Committee for the Invokana Multidistrict
Judge Brian R. Martinotti of the District of New Jersey entered an order on Jan. 24 appointing Holly Dolejsi to the Plaintiffs’ Steering Committee for the Invokana multidistrict litigation.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.